Asset Management One Co. Ltd. Has $2.19 Million Position in DaVita Inc. (NYSE:DVA)

Asset Management One Co. Ltd. reduced its holdings in DaVita Inc. (NYSE:DVA) by 3.7% during the 4th quarter, according to the company in its most recent disclosure with the SEC. The fund owned 20,964 shares of the company’s stock after selling 795 shares during the quarter. Asset Management One Co. Ltd.’s holdings in DaVita were worth $2,189,000 as of its most recent filing with the SEC.

Several other hedge funds have also made changes to their positions in the stock. Arizona State Retirement System lifted its stake in shares of DaVita by 1.4% in the fourth quarter. Arizona State Retirement System now owns 15,056 shares of the company’s stock valued at $1,577,000 after buying an additional 210 shares during the period. TIAA Trust National Association lifted its stake in shares of DaVita by 29.7% in the fourth quarter. TIAA Trust National Association now owns 6,554 shares of the company’s stock valued at $687,000 after buying an additional 1,500 shares during the period. State of Michigan Retirement System lifted its stake in DaVita by 0.6% during the fourth quarter. State of Michigan Retirement System now owns 15,939 shares of the company’s stock worth $1,670,000 after purchasing an additional 100 shares during the period. Oak Thistle LLC bought a new position in DaVita during the fourth quarter worth about $372,000. Finally, Fifth Third Bancorp lifted its stake in DaVita by 29.5% during the fourth quarter. Fifth Third Bancorp now owns 4,271 shares of the company’s stock worth $447,000 after purchasing an additional 973 shares during the period. Institutional investors own 90.12% of the company’s stock.

Analysts Set New Price Targets

A number of brokerages have commented on DVA. TheStreet upgraded shares of DaVita from a “c+” rating to a “b-” rating in a research note on Wednesday, February 7th. StockNews.com upgraded shares of DaVita from a “buy” rating to a “strong-buy” rating in a research note on Monday, April 8th. Barclays started coverage on shares of DaVita in a research note on Wednesday, March 6th. They issued an “equal weight” rating and a $133.00 target price for the company. UBS Group lifted their target price on shares of DaVita from $113.00 to $134.00 and gave the company a “buy” rating in a research note on Wednesday, February 14th. Finally, Truist Financial lifted their target price on shares of DaVita from $130.00 to $135.00 and gave the company a “hold” rating in a research note on Tuesday, February 20th. Two investment analysts have rated the stock with a hold rating, one has issued a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat, DaVita currently has an average rating of “Moderate Buy” and a consensus price target of $118.50.

Insider Activity at DaVita

In related news, CEO Javier Rodriguez sold 67,603 shares of the business’s stock in a transaction on Monday, February 26th. The shares were sold at an average price of $126.11, for a total value of $8,525,414.33. Following the sale, the chief executive officer now directly owns 488,697 shares of the company’s stock, valued at approximately $61,629,578.67. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. In other DaVita news, insider James O. Hearty sold 26,164 shares of the business’s stock in a transaction dated Friday, February 16th. The shares were sold at an average price of $119.64, for a total transaction of $3,130,260.96. Following the sale, the insider now directly owns 20,264 shares of the company’s stock, valued at approximately $2,424,384.96. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, CEO Javier Rodriguez sold 67,603 shares of the business’s stock in a transaction dated Monday, February 26th. The stock was sold at an average price of $126.11, for a total transaction of $8,525,414.33. Following the sale, the chief executive officer now directly owns 488,697 shares in the company, valued at $61,629,578.67. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 134,540 shares of company stock valued at $16,551,071. 1.40% of the stock is owned by corporate insiders.

DaVita Price Performance

DVA opened at $130.42 on Friday. DaVita Inc. has a 52 week low of $71.51 and a 52 week high of $141.54. The firm has a market capitalization of $11.44 billion, a PE ratio of 17.62, a P/E/G ratio of 1.17 and a beta of 1.04. The company has a debt-to-equity ratio of 6.65, a quick ratio of 1.13 and a current ratio of 1.19. The company has a fifty day moving average price of $128.95 and a two-hundred day moving average price of $107.88.

DaVita (NYSE:DVA) last announced its quarterly earnings results on Tuesday, February 13th. The company reported $1.87 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.53 by $0.34. DaVita had a net margin of 5.70% and a return on equity of 64.42%. The company had revenue of $3.15 billion during the quarter, compared to analyst estimates of $3.01 billion. During the same quarter in the previous year, the business earned $1.11 EPS. The firm’s revenue was up 7.8% on a year-over-year basis. As a group, analysts anticipate that DaVita Inc. will post 9.23 earnings per share for the current year.

DaVita Company Profile

DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.